文献速递肝病

儿童非酒精性脂肪性肝病生活方式、饮食及药物治疗评估:一项系统综述

Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-05-29

该系统综述检索至2018年1月7日的随机对照试验,纳入21项已发表试验共1307例患儿(平均年龄12.6岁,63%男性,平均干预8个月),评估生活方式、多不饱和脂肪酸、抗氧化剂等治疗。研究发现试验终点和纳入标准异质性大,仅14%以组织学特征为主要终点,抗氧化剂似乎可减轻部分脂肪性肝炎特征但未获组织学验证。

要点

  • 21项随机对照试验共1307例患儿,平均年龄12.6岁,63%男性,平均干预8个月。
  • 仅38%试验以活检证实的非酒精性脂肪性肝病为纳入标准,仅14%以组织学特征为主要终点。
  • 抗氧化剂似乎可减轻部分脂肪性肝炎组织学特征,但生活方式、多不饱和脂肪酸或益生菌的疗效未获组织学验证。

核心结论

  • 儿童非酒精性脂肪性肝病已发表和正在进行的随机对照试验在研究终点和纳入标准上存在大量异质性,少数试验纳入组织学分析。
  • 抗氧化剂似乎可减轻部分脂肪性肝炎特征;生活方式调整、多不饱和脂肪酸或益生菌治疗的效应尚未通过组织学分析验证。
  • 正在进行的试验以磁共振成像量化脂肪变性为主要结局,预期将提供相关数据。

研究设计与样本

  • 系统综述检索了截至2018年1月7日的发表数据库和临床试验注册库,纳入儿童(<18岁)非酒精性脂肪性肝病的随机对照试验(已发表和正在进行)。
  • 最终分析纳入21项随机对照试验,共1307例参与者,平均年龄12.6岁,63%男性,平均干预持续时间8个月。
  • 试验质量采用改良版Cochrane偏倚风险工具评估。

主要发现

  • 大多数研究评估生活方式干预减重(n=8)、口服多不饱和脂肪酸治疗(n=6)或口服抗氧化剂治疗(n=7)。
  • 非酒精性脂肪性肝病生物标志物随减重而下降,但大多数研究未纳入组织学数据。
  • 抗氧化剂试验异质性大;部分报告脂肪性肝炎组织学特征减轻,对甘油三酯或胰岛素抵抗无影响。
  • 多不饱和脂肪酸和益生菌降低了脂肪变性的影像学标志物、胰岛素抵抗和甘油三酯水平。
  • 仅38%的试验以活检证实的非酒精性脂肪性肝病作为纳入标准;10项研究(48%)以转氨酶水平或超声检查结果作为主要终点,仅3项试验(14%)以组织学特征作为主要终点。

局限性

  • 试验主要终点存在异质性。
  • 大多数研究未纳入组织学数据。
  • 抗氧化剂试验异质性大。
  • 仅38%的试验以活检证实的非酒精性脂肪性肝病作为纳入标准。
  • 生活方式调整、多不饱和脂肪酸或益生菌治疗的效应尚未通过组织学分析验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are no approved treatments for pediatric nonalcoholic fatty liver disease (NAFLD) and there is a lack of consensus on the best outcome measure for randomized controlled trials. We performed a systematic review of treatments tested for pediatric NAFLD, the degree of heterogeneity in trial design, and endpoints analyzed in these studies. METHODS: We searched publication databases and clinical trial registries through January 7, 2018 for randomized controlled trials (published and underway) of children (<18 years) with NAFLD. We assessed improvements in histologic features, radiologic and biochemical markers of reduced fibrosis, metabolic syndrome parameters, and adverse events. The quality of the trials was assessed using a modified version of the Cochrane risk of bias tool. RESULTS: Our final analysis included 21 randomized controlled trials, comprising 1307 participants (mean age, 12.6 years; 63% male; mean duration of intervention, 8 months). Most studies evaluated weight loss with lifestyle intervention (n=8), oral polyunsaturated fatty acid treatment (PUFAs, n=6), or oral antioxidant treatment (n=7). Biomarkers of NAFLD decreased with weight loss, but most studies did not include histologic data. Trials of antioxidants were heterogeneous; some reported reduced histologic features of steatohepatitis with no effect on triglycerides or insulin resistance. PUFAs and probiotics reduced radiologic markers of steatosis, insulin resistance, and levels of triglycerides. Only 38% of the trials had biopsy-proven NAFLD as an inclusion criterion. There was heterogeneity in trial primary endpoints; 10 studies (48%) used levels of aminotransferases or ultrasonography findings as a primary endpoint and only 3 trials (14%) used histologic features as the primary endpoint. We identified 13 randomized controlled trials that are underway in children with NAFLD. None of the protocols include collection of liver biopsies; 9 trials (69%) will use magnetic resonance imaging quantification of steatosis as a primary outcome. CONCLUSIONS: In a systematic review of published and active randomized controlled trials of children with NAFLD, we found a large amount of heterogeneity in study endpoints and inclusion criteria. Few trials included histologic analyses. Antioxidants appear to reduce some features of steatohepatitis. Effects of treatment with lifestyle modification, PUFAs, or probiotics have not been validated with histologic analysis. Trials that are underway quantify steatosis magnetic resonance imaging-outcomes are anticipated.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Mann JP, Tang GY, Nobili V, et al. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018. PMID: 29857146. doi:10.1016/j.cgh.2018.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。